ONK Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- ONK Therapeutics's estimated annual revenue is currently $7.4M per year.
- ONK Therapeutics's estimated revenue per employee is $155,000
Employee Data
- ONK Therapeutics has 48 Employees.
- ONK Therapeutics grew their employee count by 9% last year.
ONK Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder, Advisor and Member Board | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Head Process Development | Reveal Email/Phone |
4 | Head Manufacturing | Reveal Email/Phone |
5 | Chief Scientific Officer | Reveal Email/Phone |
6 | Founder and Chief Scientific Officer | Reveal Email/Phone |
7 | Chief Operating Officer | Reveal Email/Phone |
8 | R&D Project Manager | Reveal Email/Phone |
9 | R&D Program Manager | Reveal Email/Phone |
10 | Finance Manager | Reveal Email/Phone |
ONK Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is ONK Therapeutics?
ONK Therapeutics, is an innovative cell therapy company dedicated to developing a next generation of off-the-shelf, dual-targeted NK cell therapy platform targeting solid and hematological cancers. The Company was founded in 2015, by Prof. O'Dwyer MD, of NUI Galway, an expert in translational multiple myeloma research, the tumour microenvironment, and exploitation of NK cells as cellular immunotherapy. Its core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumour antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway (i.e. DR4 or DR5). This promising new approach has the potential to enhance efficacy by addressing both intrinsic (e.g. CAR engagement of a tumor specific antigen) and extrinsic (e.g. signalling through the death receptor pathway) apoptotic pathways, and to reduce the susceptibility to possible target antigen escape through the engagement of tumor antigen independent TRAILv.
keywords:N/AN/A
Total Funding
48
Number of Employees
$7.4M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ONK Therapeutics News
Intellia Therapeutics, a gene-editing company, and ONK Therapeutics, a company developing natural killer (NK) cell therapies in oncology,...
ONK Therapeutics is an innovative cell therapy company dedicated to developing the next generation of optimally engineered, off-the-shelf,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.4M | 52 | 37% | N/A |
#2 | N/A | 57 | 24% | N/A |
#3 | $7.4M | 57 | 8% | N/A |
#4 | $5.1M | 57 | 30% | N/A |
#5 | $5.3M | 58 | -2% | N/A |